Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00007501 · ClinicalTrials.gov registry record · Phase 3

Shingles Prevention Study

A Phase 3 study, sponsored by US Department of Veterans Affairs.

Completed
Registry status
Phase 3
Development phase
38,456
Enrollment target

NCT00007501 is a Phase 3 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 38,456 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00007501, a Phase 3 study, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
Phase 3
Development phase
38,456 participants
Enrollment target

Study Summary

The incidence and severity of HZ (or shingles), as well as the frequency and severity of its complications, increases markedly with increasing age. More than half of all cases occur in persons over the age of 60. Even without complications, HZ can interfere with an elderly patient's ability to perform essential activities of daily living, resulting in a loss of independence that is emotionally devastating and frequently irreversible. The most common complication of HZ in elderly persons is postherpetic neuralgia (PHN), which frequently results in disordered sleep, chronic fatigue, anxiety and severe depression. Antiviral therapy has a modest impact on the acute phase of HZ. However, it does not appear to prevent the development of PHN. This study is a 5.5 year randomized, double-blind, placebo-controlled, efficacy trial to determine whether vaccination with live-attenuated Oka/Merck varicella-zoster decreases the incidence and/or severity of herpes zoster (HZ) and its complications in adults 60 years of age and older.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Varicella-zoster vaccine

Trial Details

FieldValue
Enrollment Target 38,456 participants
Start Date 1998-11
Est. Completion 2011-02
Phase Phase 3

Sponsor

US Department of Veterans Affairs

632 total trials

What the Registry Record Tells You About NCT00007501

The ClinicalTrials.gov registry entry for NCT00007501 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 38,456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00007501 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00007501 about?

NCT00007501 is a clinical study titled "Shingles Prevention Study". The incidence and severity of HZ (or shingles), as well as the frequency and severity of its complications, increases markedly with increasing age. More than half of all cases occur in persons over the age of 60. Even without complications, HZ can interfere with an elderly patient's ability to perfo...

What is the current status of trial NCT00007501?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 38,456 participants. The study started on 1998-11. Estimated completion is 2011-02.

What interventions are being tested in trial NCT00007501?

The interventions under investigation include: Placebo (BIOLOGICAL), Varicella-zoster vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00007501?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.